Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Akero Therapeutics Inc (AKRO) USD0.0001

Sell:$23.73 Buy:$23.79 Change: $0.39 (1.62%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.39 (1.62%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.39 (1.62%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. The Company's lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, which targets the inflammation and fibrosis of the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).

Contact details

601 Gateway Boulevard, Suite 350
United States
+1 (650) 4876488

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$815.77 million
Shares in issue:
34.86 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Andrew Cheng
    President, Chief Executive Officer, Director
  • Jonathan Young
    Co-Founder, Chief Operating Officer, Executive Vice President, Secretary
  • Timothy Rolph
    Co-Founder, Chief Scientific Officer
  • William White
    Chief Financial Officer, Executive Vice President and Head of Corporate Development and Treasurer
  • Kitty Yale
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.